Efficacy of combination of ATRA, ATO and anthracyclines induction therapy in patients with acute promyelocytic leukemia
10.3760/cma.j.issn.0253-2727.2017.06.011
- VernacularTitle: 全反式维甲酸、砷剂联合蒽环类药物诱导方案治疗急性早幼粒细胞白血病的疗效分析
- Author:
Rongjun MA
1
;
Zunmin ZHU
;
Xiaoli YUAN
;
Li JIANG
;
Shiwei YANG
;
Jing YANG
;
Jianmin GUO
;
Lin ZHANG
;
Pingchong LEI
;
Zhen WANG
;
Yuzhu ZANG
;
Yuqing CHEN
;
Tongbao WANG
;
Dai KONG
;
Kai SUN
;
Yin ZHANG
Author Information
1. Department of Hematology, Henan Provincial People’s Hospital, Zhengzhou 450003, China
- Publication Type:Journal Article
- Keywords:
Leukemia, promyelocyte, acute;
Induction therapy;
Antineoplastic combined chemoerapy protocols
- From:
Chinese Journal of Hematology
2017;38(6):523-527
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To explore the efficacies of regimens of three-drug induction therapy (ATRA+ATO+anthracyclines) versus two-drug induction therapy (ATRA+ATO) in patients with acute promyelocytic leukemia (APL).
Methods:Of 184 patients diagnosed with APL from January 2009 to March 2016, 58 patients underwent three-drug induction therapy, while the rest were treated with two-drug induction therapy. Three-drug induction therapy was of ATRA (20 mg·m-2·d-1, d1-28) + ATO (0.16 mg·kg-1·d-1, d1-28) + Idarubicin (8 mg·m-2·d-1, d3-5) /daunorubicin (40 mg·m-2·d-1, d3-5) , while two-drug induction therapy ATRA+ATO with the same doses and methods as above. Of 184 cases, 69 cases accompanied with WBC counts>10×109/L, 115 cases with WBC counts≤10×109/L at onset.
Results:①Short-term efficacy: After one cycle induction therapy, the rates of hematologic remission, genetic remission, molecular remission and induced differentiation syndrome (DS) in three-drug regimen group were 98.3%, 87.9%, 72.4% and 0 respectively, while those in two-drug regimen group were 87.3%, 65.9%, 51.6% and 12.7% respectively. In patients with WBC >10×109/L, DS rate and early mortality in three-drug regimen group were lower than in two-drug regimen group (0 vs 15.6%, 4.2% vs 15.6%, respectively). In patients with WBC≤10×109/L, DS rate in three-drug regimen group was also lower than in two-drug regimen group (0 vs 12.3%) , but there were no statistical differences in terms of relapse and early mortality. ② Long-term efficacy: The relapse rate, overall survival (OS) and disease free survival (DFS) in three-drug regimen group were 0, 98.5%, 96.6% respectively, while those in two-drug regimen group were 8.6%, 86.5% and 84.1% respectively; the advantages of three-drug over two-drug regimen, especially in cases of WBC >10×109/L were observed. ③ Side effects: the incidences of gastrointestinal reaction, liver dysfunction, myocardial damage and headache in three-drug regimen group hardly increased.
Conclusion:The efficacies of three-drug induction therapy were superior to two-drug one.
